Drug intelligence / Profile preview

letrozole + pelareorep

Development stage: Unknown
Lead developer: Oncolytics Biotech
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

Letrozole + pelareorep is a combination therapy being investigated primarily for breast cancer treatment. Pelareorep is an intravenously delivered immuno-oncolytic reovirus that selectively replicates in tumor cells, promoting immune system activation against cancer. When combined with letrozole (an aromatase inhibitor), this therapy aims to enhance anti-tumor immune responses. The combination works by pelareorep infecting and replicating within tumor cells, leading to increased tumor inflammation, T cell recruitment, and PD-L1 expression, which may improve outcomes when combined with checkpoint inhibitors.

Targets

CYP19A1 (Aromatase)Sialoglycan (Cell-surface sialoglycan)JAM-A (Junctional adhesion molecule A)

Beyond the preview

Go deeper on letrozole + pelareorep.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on letrozole + pelareorep.

Explore the full profile